Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants
- Marie Jabagi; Jérémie Cohen; Marion Bertrand; Martin Chalumeau; Mahmoud Zureik
Access Resources
About
This study looks at how well nirsevimab works to prevent hospital stays for infants with RSV-related lung infections. It uses data from France, comparing infants who got the treatment to those who didn't. The results show that nirsevimab reduces hospitalizations by 65% and is also effective in preventing more severe cases needing intensive care or breathing support. The study involved over 82,000 infants and found consistent benefits across different groups. It concludes that a single dose of nirsevimab offers strong protection against serious RSV infections in babies without any financial backing influencing the research outcomes.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.